Crews Bank & Trust Makes New Investment in GSK plc (NYSE:GSK)

Crews Bank & Trust acquired a new stake in shares of GSK plc (NYSE:GSK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 765 shares of the pharmaceutical company’s stock, valued at approximately $26,000.

Other institutional investors have also modified their holdings of the company. FMR LLC raised its holdings in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its position in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC raised its stake in shares of GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC lifted its holdings in shares of GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after acquiring an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC boosted its stake in shares of GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after purchasing an additional 83,433 shares during the period. 15.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

GSK has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Down 0.4 %

Shares of NYSE GSK opened at $35.20 on Friday. The stock has a 50 day moving average price of $34.07 and a 200 day moving average price of $37.69. The firm has a market capitalization of $72.96 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 1.37 and a beta of 0.63. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.